Published in Arch Neurol on June 01, 1979
Subacute sclerosing panencephalitis. J Neurol (2008) 1.30
Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr (2005) 1.02
A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.78
Use of isoprinosine in subacute sclerosing panencephalitis. Arch Dis Child (1980) 0.75
Subacute sclerosing panencephalitis. Br Med J (1979) 0.75
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40
Serial casting of the lower extremity to correct contractures during the acute phase of burn care. Phys Ther (1995) 1.39
Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16
Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol (1997) 1.16
Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Multifocal motor nerve conduction abnormalities in amyotrophic lateral sclerosis. J Neurol Sci (1992) 1.12
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs. J Exp Med (1975) 1.10
Fully integrated whole blood testing by real-time absorption measurement on a centrifugal platform. Lab Chip (2006) 1.09
Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci (1978) 1.09
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol (1994) 1.08
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A (1975) 1.03
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology (2011) 1.02
Integrated siphon-based metering and sedimentation of whole blood on a hydrophilic lab-on-a-disk. Biomed Microdevices (2007) 1.02
Direct costs of stroke for a Swedish population. Int J Technol Assess Health Care (1990) 1.01
Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol (1975) 1.01
Association of MS with thyroid disorders. Neurology (1999) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Regulated expression of proenkephalin A in normal lymphocytes. J Immunol (1989) 0.99
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol (2001) 0.99
Complete unilateral ophthalmoplegia as the presenting manifestation of Waldenström's macroglobulinemia. Neurology (1990) 0.99
Ictal hemiparesis. Eur Neurol (1982) 0.98
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? J Neurol (1988) 0.98
Neurologic manifestations of progressive systemic sclerosis. Arch Neurol (1992) 0.98
Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1995) 0.97
Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol (1991) 0.96
Hemianopic colour blindness. J Neurol Neurosurg Psychiatry (1975) 0.96
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest (1993) 0.95
Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics (1999) 0.95
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95
Neurological features as presenting manifestations of brucellosis. Eur Neurol (1977) 0.95
Cytokeratin expression in human thymus: immunohistochemical mapping. Cell Tissue Res (1995) 0.94
Electrophysiological examinations of the visual system in multiple sclerosis. J Neurol Sci (1973) 0.94
Treatment and prevention of acute hepatic encephalopathy by intravenous levodopa. Surgery (1974) 0.94
Asymmetrical cognitive deterioration in demented and Parkinson patients. Cortex (1981) 0.93
Cognitive dysfunction following thalamic stroke: a study of 16 cases and review of the literature. J Neurol Sci (2000) 0.93
Parkinsonism and hyperthyroidism. Eur Neurol (1974) 0.93
Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol (1986) 0.93
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol (1992) 0.91
Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res (1993) 0.91
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler (2003) 0.90
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology (1996) 0.90
Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol (1994) 0.90
Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A (1996) 0.89
Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol (1984) 0.89
Antiacetylcholine receptor antibody in neonatal myasthenia gravis. Am J Dis Child (1981) 0.89
[Is there an association between the rating of illness and injury severity and the experience of emergency medical physicians?]. Anaesthesist (2008) 0.88
Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J (1977) 0.88
Cell-mediated immunity to neural antigens in idiopathic polyneuritis and myeloradiculitis. Clinical-immunologic classification of several autoimmune demyelinating disorders. Neurology (1975) 0.88
Neurologic manifestations in patients with mixed cryoglobulinemia. Neurology (1974) 0.88
Suppressive effect of pregnancy on the development of experimental allergic encephalomyelitis in rabbits. Am J Reprod Immunol (1984) 0.87
Associative visual agnosia without alexia. Neurology (1975) 0.87
Neuritogenic and encephalitogenic properties of the peripheral nerve basic proteins. J Neuropathol Exp Neurol (1975) 0.87
Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. J Neurol (1986) 0.86
Acetoacetate and D-(-)-beta-hydroxybutyrate as precursors for sterol synthesis by calf oligodendrocytes in suspension culture: extramitochondrial pathway for acetoacetate metabolism. J Neurochem (1979) 0.86
Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler (2003) 0.86
Expression of alpha-smooth muscle actin in murine bone marrow stromal cells. Blood (1991) 0.86
Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci Res (2000) 0.85
Evaluation of the effect of stress on the blood--brain barrier: critical role of the brain perfusion time. Brain Res (2001) 0.85
Gabapentin may be hazardous in myasthenia gravis. Muscle Nerve (2000) 0.85
Antibodies to galactocerebroside bind to oligodendroglia in suspension culture. J Neurol Sci (1979) 0.85
Development of novel therapies for MG: Studies in animal models. Autoimmunity (2010) 0.85
Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler (1999) 0.84
Cerebral dominance for consciousness. Arch Neurol (1976) 0.84
Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 [correction of interlukin-6] in astrocytes. Int J Dev Neurosci (1999) 0.84
Myasthenia gravis in the elderly. J Am Geriatr Soc (1976) 0.84
Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol (1995) 0.84
Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol (1994) 0.84
Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient. Neurology (1992) 0.83
Aggravation of human and experimental myasthenia gravis by contrast media. Neurology (1990) 0.83
Familial inflammatory demyelinating polyneuropathy: a Guillain-Barré syndrome variant without autoimmune predilection. J Neurol Neurosurg Psychiatry (1994) 0.83
Adult-onset Niemann-Pick type C disease. Clinical, biochemical, and genetic study. Arch Neurol (1997) 0.83